title: Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population.
abstract: BACKGROUND
  The tumor suppressor TP53 and its negative regulator MDM2 play crucial roles in carcinogenesis. Previous case-control studies also revealed TP53 72Arg>Pro and MDM2 309T>G polymorphisms contribute to the risk of common cancers. However, the relationship between these two functional polymorphisms and nasopharyngeal carcinoma (NPC) susceptibility has not been explored.
  
  
  METHODS
  In this study, we performed a case-control study between 522 NPC patients and 722 healthy controls in a Chinese population by using PCR-RFLP.
  
  
  RESULTS
  We found an increased NPC risk associated with the MDM2 GG (odds ratio [OR] = 2.83, 95% confidence interval [CI] = 2.08-3.96) and TG (OR = 1.49, 95% CI = 1.16-2.06) genotypes. An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.22, 95% CI = 1.58-3.10) compared to the Arg/Arg genotype. The gene-gene interaction of MDM2 and TP53 polymorphisms increased adult NPC risk in a more than multiplicative manner (OR for the presence of both MDM2 GG and TP53 Pro/Pro genotypes = 7.75, 95% CI = 3.53-17.58).
  
  
  CONCLUSIONS
  The findings suggest that polymorphisms of MDM2 and TP53 genes may be genetic modifier for developing NPC.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, The second affected hospital to Nanchang University, Nanchang, China.
authors.forename: Mang
authors.initials: M
authors.lastname: Xiao
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Xinhua
authors.initials: X
authors.lastname: Zhu
authors.forename: Jun
authors.initials: J
authors.lastname: Huang
authors.forename: Huifen
authors.initials: H
authors.lastname: Jiang
authors.forename: Sunhong
authors.initials: S
authors.lastname: Hu
authors.forename: Yuehui
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D016158:Genes, p53; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D051736:Proto-Oncogene Proteins c-mdm2 / Q000096:biosynthesis / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics; D055815:Young Adult
chemical_list: D012333:RNA, Messenger; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2
references.citation: Nat Genet. 2003 Mar;33(3):357-65
references.pmid: 12567188
references.citation: Cell. 2004 Nov 24;119(5):591-602
references.pmid: 15550242
references.citation: Nucleic Acids Res. 1990 Aug 25;18(16):4961
references.pmid: 1975675
references.citation: Mol Cell Biol. 1999 Feb;19(2):1092-100
references.pmid: 9891044
references.citation: Clin Cancer Res. 2007 May 1;13(9):2627-33
references.pmid: 17473193
references.citation: Carcinogenesis. 2007 Sep;28(9):1996-2001
references.pmid: 17638920
references.citation: Hum Genet. 1994 Jun;93(6):620-4
references.pmid: 8005584
references.citation: Int J Cancer. 2009 Oct 1;125(7):1735-8
references.pmid: 19521985
references.citation: Arch Med Res. 2009 May;40(4):299-305
references.pmid: 19608020
references.citation: Science. 1990 Nov 30;250(4985):1233-8
references.pmid: 1978757
references.citation: Nature. 1992 Mar 19;356(6366):215-21
references.pmid: 1552940
references.citation: J Clin Oncol. 2008 May 10;26(14):2252-7
references.pmid: 18467716
references.citation: Hum Mutat. 2002 Jun;19(6):607-14
references.pmid: 12007217
references.citation: Nucleic Acids Res. 1998 Aug 1;26(15):3453-9
references.pmid: 9671804
references.citation: Cancer Lett. 2008 Mar 8;261(1):21-5
references.pmid: 18248785
references.citation: Blood. 1995 Mar 15;85(6):1580-9
references.pmid: 7888675
references.citation: Carcinogenesis. 2002 Mar;23(3):381-7
references.pmid: 11895852
references.citation: Cancer Res. 1999 Jan 1;59(1):1-7
references.pmid: 9892174
references.citation: BMC Cancer. 2008 Apr 23;8:116
references.pmid: 18433491
references.citation: Cancer Genet Cytogenet. 1993 Apr;66(2):83-92
references.pmid: 8500106
references.citation: Nucleic Acids Res. 2001 Sep 1;29(17):E88-8
references.pmid: 11522844
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2717-23
references.pmid: 18086778
references.citation: Methods. 2001 Dec;25(4):409-18
references.pmid: 11846610
references.citation: Carcinogenesis. 2008 Nov;29(11):2120-5
references.pmid: 18701437
references.citation: Eur J Cancer. 2008 Mar;44(5):760-6
references.pmid: 18313915
references.citation: Leuk Res. 2009 Nov;33(11):1454-8
references.pmid: 19423162
references.citation: Cancer Res. 2007 Jun 15;67(12):5831-9
references.pmid: 17575151
references.citation: Hum Mutat. 2006 Jan;27(1):110-7
references.pmid: 16287156
references.citation: Cancer Res. 2005 Oct 15;65(20):9582-7
references.pmid: 16230424
references.citation: Blood. 1991 Mar 15;77(6):1153-6
references.pmid: 1705829
references.citation: Nat Rev Cancer. 2002 Aug;2(8):594-604
references.pmid: 12154352
references.citation: Cell. 2009 May 15;137(4):609-22
references.pmid: 19450511